AnGes, Inc. Announces Consolidated Earnings Results for the First Nine Months Ended September 30, 2019; Provides Earnings Guidance for the Full Year Ending December 31, 2019
October 27, 2019
Share
AnGes, Inc. announced consolidated earnings results for the first nine months ended September 30, 2019. For the nine months, the company announced revenues of JPY 323 million against JPY 276 million a year ago. Operating loss was JPY 2,358 million against JPY 2,242 million a year ago. Net loss was JPY 2,770 million or JPY 26.65 per share against JPY 2,202 million or JPY 26.12 per share a year ago.
The company provided earnings guidance for the full year ending December 31, 2019. For the full year, the company expects to report revenues of JPY 335 million, operating loss of JPY 3,300 million, ordinary loss of JPY 3,300 million and net loss of JPY 3,700 million or JPY 35.33 per share.
AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
AnGes, Inc. Announces Consolidated Earnings Results for the First Nine Months Ended September 30, 2019; Provides Earnings Guidance for the Full Year Ending December 31, 2019
ANGES, INC. 
